Topline Capital Management LLC Purchases Shares of 546,471 Certara, Inc. $CERT

Topline Capital Management LLC acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 546,471 shares of the company’s stock, valued at approximately $6,678,000. Certara accounts for 1.1% of Topline Capital Management LLC’s investment portfolio, making the stock its 20th biggest holding. Topline Capital Management LLC owned about 0.34% of Certara at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. iSAM Funds UK Ltd lifted its stake in shares of Certara by 68.6% during the 3rd quarter. iSAM Funds UK Ltd now owns 34,141 shares of the company’s stock worth $417,000 after buying an additional 13,891 shares during the last quarter. Nicolet Advisory Services LLC grew its stake in Certara by 7.4% in the 3rd quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock valued at $396,000 after buying an additional 2,100 shares during the last quarter. Alpha Wave Global LP acquired a new position in Certara in the 3rd quarter valued at about $6,168,000. Brown Brothers Harriman & Co. raised its holdings in Certara by 34.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock valued at $45,996,000 after acquiring an additional 972,669 shares during the period. Finally, Invesco Ltd. raised its holdings in Certara by 10.2% in the 3rd quarter. Invesco Ltd. now owns 577,501 shares of the company’s stock valued at $7,057,000 after acquiring an additional 53,536 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Stock Up 1.4%

Shares of CERT opened at $6.65 on Friday. Certara, Inc. has a one year low of $6.04 and a one year high of $15.38. The company has a market cap of $1.06 billion, a P/E ratio of -665.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. The firm has a 50 day simple moving average of $7.98 and a two-hundred day simple moving average of $9.62.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same period in the prior year, the business posted $0.15 EPS. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Ratings Changes

CERT has been the subject of a number of research analyst reports. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research note on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Certara in a report on Thursday, February 26th. Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a research note on Thursday, February 26th. Finally, Stephens decreased their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $11.10.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.